섬망 치료에 있어 Aripiprazole과 Haloperidol의 효과 및 부작용 비교
Comparison of Efficacy and Side Effects between Aripiprazole and Haloperidol in the Treatment of Delirium
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives:To compare the efficacy and the safety of aripiprazole and haloperidol in the treatment of patients with delirium. Methods:26 patients with delirium were randomized to receive either aripiprazole or haloperidol and finally 20 patients were analyzed. We collected demographic and clinical data. The Korean Version of Delirium Rating Scale-revised-98 (K-DRS-98) and Korean Version of Drug Induced Extrapyramidal Symptom Scale (DIEPSS-K) were assessed. Blood samples were collected to an- alyze serum sodium ion concentration, plasma cortisol and prolactin level and pulse oximetry was used for measuring oxygen satu- ration. Results:K-DRS-98 severity scores decreased in both groups significantly over the study period, but no statistically significant difference was observed between the two groups. No significant extrapyramidal syndromes were noted in both groups, but the use of haloperidol was associated with increased plasma prolactin level (From 24.0±28.1 ng/mL to 32.0±20.0 ng/mL, p=0.005). Conclusion:Aripiprazole is as effective as haloperidol in the treatment of delirium and aripiprazole may be safer than haloperi- dol in that haloperidol is associated with increased plasma prolactin level.
Abstract
Objectives:To compare the efficacy and the safety of aripiprazole and haloperidol in the treatment of patients with delirium. Methods:26 patients with delirium were randomized to receive either aripiprazole or haloperidol and finally 20 patients were analyzed. We collected demographic and clinical data. The Korean Version of Delirium Rating Scale-revised-98 (K-DRS-98) and Korean Version of Drug Induced Extrapyramidal Symptom Scale (DIEPSS-K) were assessed. Blood samples were collected to an- alyze serum sodium ion concentration, plasma cortisol and prolactin level and pulse oximetry was used for measuring oxygen satu- ration. Results:K-DRS-98 severity scores decreased in both groups significantly over the study period, but no statistically significant difference was observed between the two groups. No significant extrapyramidal syndromes were noted in both groups, but the use of haloperidol was associated with increased plasma prolactin level (From 24.0±28.1 ng/mL to 32.0±20.0 ng/mL, p=0.005). Conclusion:Aripiprazole is as effective as haloperidol in the treatment of delirium and aripiprazole may be safer than haloperi- dol in that haloperidol is associated with increased plasma prolactin level.
참고문헌 (35)
- Trzepacz P, "Neuropsychiatric aspects of delirium, in The American Psychiatric Publishing Group textbook of neuropsychiatry", pp.447~470 (1997), American Psychiatric Publishing Group
- Siddiqui N, "Occurrence and outcome of delirium in medical in-patients: a systematic literature review", Age Ageing, 35, pp.350~364 (2006)
- Inouye SK, "Precipitating factors for delirium in hospitalized elderly persons. Predictive model and interrelationship with baseline vulnerability", JAMA, 275, pp.852~857 (1996)
- Stagno D, "The delirium subtypes: a review of prevalence, phenomenology, pathophysiology, and treatment response", Palliat Support Care, 2, pp.171~179 (2004)
- Kim SK, "Delirium due to general medical condition", J Korean Geriatric Psychiatr, 12, pp.62~73 (2008)
- Marshall JC, "Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome", Crit Care Med, 29, pp.S99~S106 (2001)
- Robertsson B, "Hyperactivity in the hypothalamic pituitary adrenal axis in demented patients with delirium", Int Clin Psychopharmacol, 16, pp.39~47 (2001)
- Perry EK, "Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness", Brain Cogn, 28, pp.240~258 (1995)
- Bertrand N, "Post-ischemic regional changes in acetylcholine synthesis following transient forebrain ischemia in gerbils", Neurochem Res, 17, pp.321~325 (1992)
- Maldonado JR, "Pathoetiological model of delirium: a comprehensive understanding of the neurobiology of delirium and an evidence-based approach to prevention and treatment", Crit Care Clin, 24, pp.789~785 (2008)
- Trzepacz PT, "Validation of the Delirium Rating Scale-Revised-98: Comparison with the Delirium Rating Scale and the Cognitive Test for Delirium", J Neuro.psychiatry Clin Neurosci, 13(2), pp.229~224 (2001)
- 임경옥, "한국판 섬망 평가 척도-98(K-DRS-98)의 표준화 연구", 신경정신의학, 45(6), pp.518~526 (2006), 대한신경정신의학회
- Attard A, "Delirium and its treatment", CNS Drugs, 22, pp.631~644 (2008)
- Lacasse H, "Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients", Ann Pharmacother, 40, pp.1966~1973 (2006)
- Boettger S, "Atypical antipsychotics in the management of delirium: a review of the empirical literature", Palliat Support Care, 3, pp.227~237 (2005)
- Schwartz TL, "The role of atypical antipsychotics in the treatment of delirium", Psychosomatics, 43, pp.171~174 (2002)
- Han CS, "A DOUBLE-BLIND TRIAL OF RISPERIDONE AND HALOPERIDOL FOR THE TREATMENT OF DELIRIUM", PSYCHOSOMATICS, 45, pp.297~301 (2004)
- Skrobik YK, "Olanzapine vs haloperidol: treating delirium in a critical care setting", Intensive Care Med, 30, pp.444~449 (2004)
- Kim KY, "Treatment of delirium in older adults with quetiapine", J Geriatr Psychiatry Neurol, 16, pp.29~31 (2003)
- Leso L, "Ziprasidone treatment of delirium", Psychosomatics, 43, pp.61~62 (2002)
- Straker DA, "Aripiprazole in the treatment of delirium", Psychosomatics, 47, pp.385~391 (2006)
- Alao AO, "Aripiprazole and delirium", Ann Clin Psychiatry, 18, pp.267~269 (2006)
- Stephen M, "Stahl’s essential psychopharmacology: neuroscientific basis and practical applications", pp.414~422 (2007), Cambridge University press
- Kane JM, "Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks", Schizophr Res, 95, pp.143~150 (2007)
- Naber D, "Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism", Prog Neuropsychopharmacol Biol Psychiatry, 28, pp.1213~1219 (2004)
- Veselinović T, "Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion", J Clin Psychopharmacol, 31, pp.214~220 (2011)
- 정도운, "Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: A placebo-controlled trial", American Journal of Psychiatry, 164(9), pp.1404~1410, American Psychiatric Publishing, Inc.
- Hoffer ZS, "Evidence for the partial dopamine- receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia", Psychosomatics, 50, pp.317~324 (2009)
- Byerly M, "Clinical implications of Antipsychotic induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders", J Clin Psychopharmacol, 27, pp.639~661 (2007)
- Boettger S, "Aripiprazole and haloperidol in the treatment of delirium", Aust N Z J Psychiatry (2011)
- 김종훈, "약물에 의한 추체외로 증상 평가 척도(DIEPSS)의 한국어판 개발: 신뢰도 및 타당도 연구", 석사, pp.2002
- 이철순, "Aripiprazole과 Haloperidol의 섬망 치료에 대한 효과 비교", 대한정신약물학회지, 18(4), pp.240~245 (2007), 대한정신약물학회
- Fries E, "The cortisol awakening response (CAR): facts and future directions", Int J Psychophysiol, 72, pp.67~73 (2009)
- Muench J, "Adverse effects of antipsychotic medications", Am Fam Physician, 81, pp.617~622 (2010)
- Woods SW, "Chlorpromazine equivalent doses for the newer atypical antipsychotics", J Clin Psychiatry, 64, pp.663~667 (2003)